PNC Financial Services Group’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-54,474
| Closed | -$2.19M | – | 5220 |
|
|
2026
Q1 | $2.19M | Buy |
54,474
+948
| +2% | +$20.4K | ﹤0.01% | 966 |
|
|
2025
Q4 | $1.34M | Sell |
53,526
-526
| -1% | -$12.3K | ﹤0.01% | 1128 |
|
|
2025
Q3 | $1.22M | Sell |
54,052
-4,804
| -8% | -$112K | ﹤0.01% | 1148 |
|
|
2025
Q2 | $1.02M | Buy |
58,856
+465
| +0.8% | +$8.61K | ﹤0.01% | 1179 |
|
|
2025
Q1 | $1.28M | Buy |
58,391
+238
| +0.4% | +$6.58K | ﹤0.01% | 1072 |
|
|
2024
Q4 | $1.86M | Sell |
58,153
-309
| -0.5% | -$9.29K | ﹤0.01% | 934 |
|
|
2024
Q3 | $1.69M | Sell |
58,462
-626
| -1% | -$23.2K | ﹤0.01% | 974 |
|
|
2024
Q2 | $2.27M | Buy |
59,088
+478
| +0.8% | +$21.6K | ﹤0.01% | 862 |
|
|
2024
Q1 | $3.45M | Sell |
58,610
-61,175
| -51% | -$3.9M | ﹤0.01% | 742 |
|
|
2023
Q4 | $7.17M | Buy |
119,785
+45
| +0% | +$2.28K | 0.01% | 564 |
|
|
2023
Q3 | $4.55M | Sell |
119,740
-2,611
| -2% | -$115K | ﹤0.01% | 652 |
|
|
2023
Q2 | $11.1M | Buy |
122,351
+60,886
| +99% | +$5.25M | 0.01% | 468 |
|
|
2023
Q1 | $4.05M | Buy |
61,465
+510
| +0.8% | +$29.4K | ﹤0.01% | 689 |
|
|
2022
Q4 | $3.15M | Buy |
60,955
+3,009
| +5% | +$160K | ﹤0.01% | 748 |
|
|
2022
Q3 | $3.96M | Buy |
57,946
+194
| +0.3% | +$11.5K | ﹤0.01% | 673 |
|
|
2022
Q2 | $2.61M | Buy |
57,752
+53
| +0.1% | +$2.42K | ﹤0.01% | 799 |
|
|
2022
Q1 | $2.93M | Buy |
57,699
+44,751
| +346% | +$1.98M | ﹤0.01% | 821 |
|
|
2021
Q4 | $612K | Buy |
12,948
+6,890
| +114% | +$271K | ﹤0.01% | 1564 |
|
|
2021
Q3 | $200K | Buy |
6,058
+110
| +2% | +$6.18K | ﹤0.01% | 2210 |
|
|
2021
Q2 | $376K | Hold |
5,948
| – | – | ﹤0.01% | 1795 |
|
|
2021
Q1 | $255K | Hold |
5,948
| – | – | ﹤0.01% | 2026 |
|
|
2020
Q4 | $340K | Hold |
5,948
| – | – | ﹤0.01% | 1744 |
|
|
2020
Q3 | $179K | Buy |
5,948
+940
| +19% | +$28.1K | ﹤0.01% | 1999 |
|
|
2020
Q2 | $164K | Buy |
5,008
+8
| +0.2% | +$257 | ﹤0.01% | 2040 |
|
|
2020
Q1 | $134K | Hold |
5,000
| – | – | ﹤0.01% | 2043 |
|
|
2019
Q4 | $154K | Sell |
5,000
-3,760
| -43% | -$104K | ﹤0.01% | 2232 |
|
|
2019
Q3 | $210K | Sell |
8,760
-1,100
| -11% | -$30.3K | ﹤0.01% | 2103 |
|
|
2019
Q2 | $251K | Sell |
9,860
-4,280
| -30% | -$87.1K | ﹤0.01% | 2035 |
|
|
2019
Q1 | $276K | Buy |
14,140
+4,760
| +51% | +$74.9K | ﹤0.01% | 1952 |
|
|
2018
Q4 | $124K | Buy |
9,380
+2,440
| +35% | +$37.4K | ﹤0.01% | 2345 |
|
|
2018
Q3 | $124K | Sell |
6,940
-440
| -6% | -$8.13K | ﹤0.01% | 2465 |
|
|
2018
Q2 | $162K | Buy |
+7,380
| New | +$170K | ﹤0.01% | 2313 |
|
Other funds holding APLS
PNC Financial Services Group's APLS Position: Q2 2026 in Review
PNC Financial Services Group sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 54,474 shares — an estimated $2.19M sold.
PNC Financial Services Group first reported a position in APLS in Q2 2018 and held it in 32 quarters. The position peaked at $11.1M in Q2 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- PNC Financial Services Group reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- PNC Financial Services Group sold 54,474 Apellis Pharmaceuticals shares in Q2 2026, an estimated $2.19M.
- PNC Financial Services Group first reported a position in Apellis Pharmaceuticals in Q2 2018 and held it in 32 quarters.
- PNC Financial Services Group's Apellis Pharmaceuticals position peaked at $11.1M in Q2 2023.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.